March 08, 2009
What are we to make of Roche's new $93 per share offer for Genentech? BNET previously suggested that market conditions were so rough that Genentech holders should take the low-ball $86.50 offer that Roche made when it went hostile a few weeks ago. Looks like that was wrong! Roche chairman Franz Hume...
BNET Blogs
[ Feed -
Focus -
Exclude ]
by
Jim Edwards
at 4:18 PM
March 06, 2009
Biotech, cancer, Drugs Luke Timmerman wrote: Nowhere but America makes it possible for a company to pursue its dreams for 28 years without making a profit. Even in the most optimistic times, it’s hard to explain. So how can it possibly be, in the depths of recession, that things are looking up...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 6:00 AM
| 2 Citations
February 26, 2009
Biotech, cancer, Drugs Luke Timmerman wrote: Off the coast of the Bahamas, in sea grass more than a half-mile deep, San Diego-based Nereus Pharmaceuticals found a fungus that may be the key ingredient for an innovative new cancer drug. This will be a key year for gathering evidence that will either ...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 5:00 AM
| 1 Citations
February 14, 2009
Now that Jordan “No Soul” Green has fired me up appropriately, it’s time to do some housecleaning. RE Ryan Shell: The citizens of GSO have a word for Southside property owners: fools. Take your misbegotten Richard Florida BS and leave our city. I don’t know about you, but I...
Vie de Malchance
[ Feed -
Focus -
Exclude ]
by
Fec the Apostate
at 9:13 AM
January 25, 2009
An e-mail from Joe Roche, writing from Operation Iraqi Freedom: Amy, I'm reading John Steele Gordon's book on an economic history of the US. Great book, and fascinating reading. And it strikes me... What is missing in countering all the massive "stimulus" spending and legislation is perspective. Tha...
Amy Ridenour's National Center Blog
[ Feed -
Focus -
Exclude ]
by
Amy Ridenour
at 2:26 AM
January 08, 2009
Biotech, Hepatitis C, Life Sciences Luke Timmerman wrote: An early peek at data from Anadys Pharmaceuticals (NASDAQ: ANDS) suggests the company may have a promising new drug in the works for hepatitis C. The San Diego-based biotech is announcing results today from the first eight patients with the c...
Xconomy
[ Feed -
Focus -
Exclude ]
by
Luke Timmerman
at 7:00 AM
| 5 Citations
November 25, 2008
In the 20 years that we've published our annual list, we've covered corporate villains, scoundrels, criminals and miscreants. We've reported on some really bad stuff - from Exxon's Valdez spill to Union Carbide and Dow's effort to avoid responsibility for the Bhopal disaster; from oil companies codd...
MetaFilter
[ Feed -
Focus -
Exclude ]
by
adamvasco
at 4:51 AM
November 07, 2008
AVENUE Allure Fridays, Friday; College Night, Thursday. 649 New York Ave. NW. 202-347-8100....
Wash Post Bars and Clubs
[ Feed -
Focus -
Exclude ]
by
post
at 12:00 AM
AVENUE Allure Fridays, Friday; College Night, Thursday. 649 New York Ave. NW. 202-347-8100....
Wash Post Bars and Clubs
[ Feed -
Focus -
Exclude ]
by
post
at 12:00 AM
October 12, 2008
Bank of Ireland Frontage At the centre of Dublin, College Green provides a fine public space with the well mannered Corinthian façade of Trinity College looking down Dame Street, the ceremonial road to the former British centre of power, Dublin Castle, and the fine bank head offices and on its left...
Daithai C
[ Feed -
Focus -
Exclude ]
by
Daithai C
at 6:20 PM




